The size of new orders last December may be problematic and can't deliver expected growth in 2024.Price cuts are also a downside.Investors may need to prepare for lower-than-expected result in advance
Boomeranged on Thu, 28 Mar 2024 09:02
Based on management's FY23 results presentation, our views are:1) US remains the main battlefield of pharmaceuticals, without which future growth expectations will be discounted. 2) Mike Gallagher's early resignation doesn't mean the end of geopolitical conflicts. 3) 2024's recovery is closely related to the pace of Fed's rate cuts.24H1 may be under pressure.We'll publish related insight next week
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.